However, in the context of the recent emerging landscape of targeted agents under investigation or now approved for EGFR exon 20 insertion NSCLC, it is likely that off-label osimertinib use will be limited to patients without access to clinical trials or approved standard-of-care therapies. The gene discussed is EGFR; the disease is non-small cell lung carcinoma.